![Altimmune Inc](/common/images/company/N_ALT.png)
Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire NEW YORK, July 3, 2024 NEW YORK, July 3, 2024 /PRNewswire/ -- The Gross Law...
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyās management team will...
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire NEW YORK, June 28, 2024 NEW YORK, June 28, 2024 /PRNewswire/ -- The Gross Law...
GAITHERSBURG, Md., June 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Richard Eisenstadt, the Companyās Chief...
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT PR Newswire NEW YORK, June 25, 2024 NEW YORK, June 25, 2024 /PRNewswire/...
GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical...
GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its...
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyās management team will...
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT PR Newswire NEW YORK, June 20, 2024 NEW YORK, June 20...
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.48 | -18.998716303 | 7.79 | 8.26 | 6.255 | 2810255 | 7.47771439 | CS |
4 | 0.31 | 5.16666666667 | 6 | 8.49 | 5.99 | 5452087 | 6.9679452 | CS |
12 | -0.87 | -12.1169916435 | 7.18 | 9.5 | 5.64 | 3668811 | 7.06657957 | CS |
26 | -4.49 | -41.5740740741 | 10.8 | 14.84 | 5.64 | 4253809 | 8.80456713 | CS |
52 | 3.12 | 97.8056426332 | 3.19 | 14.84 | 2.09 | 5001385 | 7.48697369 | CS |
156 | -2.09 | -24.880952381 | 8.4 | 23.49 | 2.09 | 2679046 | 8.47140871 | CS |
260 | 3.9 | 161.825726141 | 2.41 | 35.1 | 1.45 | 2291079 | 9.96658496 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.